Evommune, Inc.

NYSE:EVMN

Biotechnology

Healthcare
$6.88 -0.82%

-$0.17 today

Market cap
$284.49M
Beta
0.10
P/E (TTM)
-9.1
EPS (TTM)
-$2.26
52W Low $13.89High $33.20

Volume 0.60M

Average 0.38M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$76.44M

FY 2025 · Annual

Investing Cash Flow

-$115.31M

FY 2025 · Annual

Financing Cash Flow

$220.76M

FY 2025 · Annual

+346.7% YoY

Cash Flow Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(34.05M)(66.81M)(68.87M)
Depreciation & Amortization1M1.29M1.39M
Deferred Income Tax000
Stock-Based Compensation000
Change in Working Capital3.34M7.42M(4.12M)
Accounts Receivables000
Inventory000
Accounts Payables125K6.51M(837K)
Other Working Capital3.22M918K(3.28M)
Other Non-Cash Items(261K)(98K)(4.84M)
Operating Cash Flow(29.97M)(58.2M)(76.44M)
Capital Expenditures(118K)(88K)(235K)
Acquisitions (Net)000
Purchases of Investments(91.31M)(90.26M)(199.17M)
Sales of Investments43M86.35M84.1M
Other Investing Activities000
Investing Cash Flow(48.43M)(3.99M)(115.31M)
Debt Repayment00(373K)
Common Stock Issued63.98M49.84M222.36M
Common Stock Repurchased000
Dividends Paid000
Other Financing Activities(230K)(423K)(1.22M)
Financing Cash Flow63.75M49.42M220.76M
Effect of Forex Changes43.67M(1)(1.21M)
Net Change in Cash29.02M(12.77M)27.81M
Free Cash Flow(30.09M)(58.28M)(76.68M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$68.9M
+ D&A$1.4M
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$4.1M
- Other Non-Cash-$4.8M
= Operating Cash Flow-$76.4M
- Capex-$235.0K
= Free Cash Flow-$76.7M

Analysis

FY2025 free cash flow is -$76.7M. FCF conversion is 111.3% of net income. Operating cash flow was -$76.4M, with capex of -$235.0K. The largest bridge item is Other Non-Cash at -$4.8M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
424B3424B3 filingNov 12, 2026
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 12, 2026
SC 13D/ASC 13D/A filingNov 10, 2026
8-KCurrent reportNov 5, 2026

Does EVMN generate free cash flow?

Evommune, Inc. (EVMN) generated -$76.68M of free cash flow in fiscal 2025.

How much operating cash flow does EVMN produce?

Operating cash flow was -$76.44M, before capital expenditures of $235,000.00.